反应详情

The title compound (552 mg) was prepared in analogy to rac-N-(3-{4-[5-(3-formyl-phenyl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide, starting from 3-formyl-5-propyl-benzoic acid (582 mg, 3.03 mmol) and N—((S)-3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide (985 mg, 3.03 mmol). LC-MS**: tR=0.78 min; [M+1]+=481.82; 1H NMR (D6-DMSO): δ 0.95 (t, J=7.3 Hz, 3H), 1.23 (t, J=7.5 Hz, 3H), 1.71 (h, J=7.5 Hz, 2H), 2.36 (s, 3H), 2.74 (q, J=7.5 Hz, 2H), 2.82 (t, J=7.5 Hz, 2H), 3.20-3.29 (m, 1H), 3.40-3.48 (m, 1H), 3.71-3.81 (m, 2H), 3.84 (d, J=4.8 Hz, 2H), 3.93-4.01 (m, 1H), 5.31 (d, J=5.0 Hz, 1H), 5.55 (t, J=5.3 Hz, 1H), 7.70 (t, J=5.5 Hz, 1H), 7.82 (s, 2H), 8.07 (s, 1H), 8.33 (s, 1H), 8.52 (s, 1H), 10.15 (s, 1H).